PMID: 90964Oct 27, 1979

Effect of alprenolol on mortality among patients with definite or suspected acute myocardial infarction. Preliminary results

M P AndersenS L Rasmussen


A double-blind study of alprenolol versus placebo was done in patients with definite or suspected myocardial infarction to show the effect of the drug on mortality-rate after a year of treatment in patients aged less than or equal to 65 and to study the tolerance of the drug by patients greater than 65 years of age. The dose given was 5--10 mg intravenously, followed by 200 mg twice a day, orally. Patients in whom beta-blockade was contraindicated were excluded. All deaths, side-effects, and dropouts were recorded. Of the 480 patients in the study, 238 patients received alprenolol and 242 placebo. During the year of follow-up 108 patients dropped out from the study. Mortality was not reduced in patients greater than 65 years of age. In those less than or equal to 65 years alprenolol significantly reduced mortality-rate (20% mortality in placebo group vs 9% in treated group). There was also a significant reduction in mortality-rate among those with definite infarction (28% in the placebo vs 15% in the treated group).


Jan 1, 1988·European Journal of Clinical Pharmacology·H PerrildN Fogh-Andersen
Jan 1, 1984·European Journal of Clinical Pharmacology·F PedersenL Skovsted
Jan 1, 1983·European Journal of Clinical Pharmacology·S L RasmussenP B Nielsen
Nov 1, 1994·Journal of General Internal Medicine·S H SialJ S Goodwin
May 1, 1983·Progress in Cardiovascular Diseases·G J Goldman, A D Pichard
Jan 1, 1983·Pharmacology & Therapeutics·A J Scriven, P J Lewis
Jan 1, 1988·Pharmacology & Therapeutics·J W UpwardC F George
Dec 1, 1981·Controlled Clinical Trials
Jun 1, 1985·Controlled Clinical Trials·R L BellC Payton-Ross
Mar 1, 1997·Progress in Cardiovascular Diseases·J B SorianoD E Grobbee
Dec 12, 1981·Lancet·R M du BoisJ C Batten
Jun 1, 1985·Journal of the American College of Cardiology·G OlssonT Lundman
Jan 31, 1980·The New England Journal of Medicine·E Braunwald
Apr 2, 1981·The New England Journal of Medicine·Norwegian Multicenter Study Group
Nov 18, 1982·The New England Journal of Medicine·S H TaylorD M Burley
Mar 29, 1984·The New England Journal of Medicine·W H FrishmanW T Friedewald
May 16, 1981·British Medical Journal·J R Mitchell
Jan 23, 1982·British Medical Journal·V M JelinekJ Gerloff
Jun 12, 1982·British Medical Journal·N S Baber, J A Lewis
Sep 11, 1982·British Medical Journal·C FurbergJ Cutler
May 1, 1981·British Heart Journal·J H JürgensenO Pedersen-Bjergaard
Jun 22, 1984·The American Journal of Medicine·C Furberg, G S May
Jan 1, 1982·International Journal of Cardiology·A J Moss
Jan 1, 1982·Annals of the New York Academy of Sciences·A Hjalmarson
Oct 1, 1983·The American Journal of Cardiology·C M Pratt, R Roberts
Jul 1, 1990·Geriatric Nursing·E B Schron, L M Friedman
Jun 15, 2014·The American Journal of Medicine·Sripal BangaloreFranz H Messerli
Jan 1, 1984·Annals of the New York Academy of Sciences·A Hjalmarson
Oct 4, 2007·Journal of the American Geriatrics Society·Karol WatsonMatthew Budoff
Mar 1, 1982·Journal of Clinical and Hospital Pharmacy·D M Burley
Jun 1, 1983·Journal of Clinical and Hospital Pharmacy·S Hutchison, L M Campbell
Mar 1, 1981·Clinical Cardiology·G SchettlerK König
Dec 18, 2019·The Cochrane Database of Systematic Reviews·Sanam SafiChristian Gluud
Jul 11, 2020·Journal of Hypertension·Costas ThomopoulosGiuseppe Mancia
Jan 1, 1986·Drug Intelligence & Clinical Pharmacy·V F Mauro, F P Zeller
Jan 1, 1984·Acta Medica Scandinavica·T GundersenA M Abrahamsen
Jan 1, 1988·Acta Medica Scandinavica·L U GerdesO Faergeman
Dec 1, 1985·Postgraduate Medicine·W H FrishmanC Furberg
Jan 1, 1982·British Journal of Clinical Pharmacology·V Hansteen
Jan 1, 1982·British Journal of Clinical Pharmacology·J A Lewis
Jun 1, 1982·British Journal of Clinical Pharmacology·J I Robertson
Jan 1, 1986·British Journal of Clinical Pharmacology·B N Prichard, C W Owens
Jan 1, 1981·Acta Medica Scandinavica. Supplementum·A Vedin, C Wilhelmsson
Mar 15, 1990·The New England Journal of Medicine·A J Moss, J Benhorin
Jul 1, 1983·British Journal of Clinical Pharmacology·H J JürgensenU Brodthagen
Jul 1, 1995·Journal of the American Geriatrics Society·K C ParkJ Y Wei
Jan 1, 1982·Acta Medica Scandinavica·H J JürgensenO Faergeman
Jan 1, 1981·Acta Medica Scandinavica. Supplementum·J R Hampton
Jan 1, 1982·British Journal of Clinical Pharmacology·J R Hampton
Jan 1, 1982·Acta Medica Scandinavica. Supplementum·J S Geddes
Jul 1, 1981·Scottish Medical Journal·D P de Bono
Jan 1, 1984·Acta Medica Scandinavica. Supplementum·H J Jürgensen
Jan 1, 1984·Acta Medica Scandinavica. Supplementum·H J JürgensenS L Rasmussen

Related Concepts

Acute Disease
Alprenolol Hydrochloride
Clinical Trials
Intravenous Injections
Myocardial Infarction

Trending Feeds


Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Systemic Juvenile Idiopathic Arthritis

Systemic juvenile idiopathic arthritis is a rare rheumatic disease that affects children. Symptoms include joint pain, but also fevers and skin rashes. Here is the latest on this disease.

Chromatin Regulation and Circadian Clocks

The circadian clock plays an important role in regulating transcriptional dynamics through changes in chromatin folding and remodelling. Discover the latest research on Chromatin Regulation and Circadian Clocks here.

Central Pontine Myelinolysis

Central Pontine Myelinolysis is a neurologic disorder caused most frequently by rapid correction of hyponatremia and is characterized by demyelination that affects the central portion of the base of the pons. Here is the latest research on this disease.

Myocardial Stunning

Myocardial stunning is a mechanical dysfunction that persists after reperfusion of previously ischemic tissue in the absence of irreversible damage including myocardial necrosis. Here is the latest research.

Pontocerebellar Hypoplasia

Pontocerebellar hypoplasias are a group of neurodegenerative autosomal recessive disorders with prenatal onset, atrophy or hypoplasia of the cerebellum, hypoplasia of the ventral pons, microcephaly, variable neocortical atrophy and severe mental and motor impairments. Here is the latest research on pontocerebellar hypoplasia.

Cell Atlas Along the Gut-Brain Axis

Profiling cells along the gut-brain axis at the single cell level will provide unique information for each cell type, a three-dimensional map of how cell types work together to form tissues, and insights into how changes in the map underlie health and disease of the GI system and its crosstalk with the brain. Disocver the latest research on single cell analysis of the gut-brain axis here.

Chronic Traumatic Encephalopathy

Chronic Traumatic Encephalopathy (CTE) is a progressive degenerative disease that occurs in individuals that suffer repetitive brain trauma. Discover the latest research on traumatic encephalopathy here.